The fusion consists of two IL-2 molecules linked to the C-terminal domain of the heavy chain of the humanized 14.18 IgG1 monoclonal antibody (mAb) that recognizes disialoganglioside (GD2) expressed on neuroblastoma and melanoma cells. The gene discussed is IL2; the disease is melanoma.